In May of this year, the European Hematology Association (EHA) produced its first guideline for the...

A time is coming when chemotherapy will no longer be used to treat chronic lymphocytic leukaemia...

The pre-planned interim analysis of the Monumental-3 trial suggests the anti-GPRC5D bispecific antibody talquetamab...

Blinatumomab (BLI), inotuzumab ozogamicin (INO), and CAR T cell therapy have reshaped the treatment of relapsed/refractory...

The CD3×CD20 bispecific antibody (bsAb), epcoritamab, is approved as monotherapy for R/R diffuse large Bcell lymphoma...

Triplet therapy with azacitidine (AZA), venetoclax (VEN), and the FLT3 inhibitor gilteritinib (GILT) induces a high...

PET-guided brentuximab vedotin, etoposide, cyclophosphamide, adrip/doxorubicin, dacarbazine, and dexamethasone (BrECADD) is an effective...

Anti-CD7 CAR T cell therapy demonstrates rapid and deep MRD-negative remission in a subset of patients...

Long-term exposure to air pollution worsens the severity of obstructive sleep apnoea (OSA), according to research...

Remote monitoring increases symptom control and reduces hospitalisations in children with asthma, according to research presented...

A randomised controlled trial (RCT) presented at the European Respiratory Society (ERS) Congress in September suggests...

Late last year, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) released its 2026 Global...